Among the 7 patients on VBI-1901 treatment long enough to have 1+ MRI scan at the time of analysis, one partial tumor response and two stable disease observations have occurred as of May 15,.
New insights on improving clinical outcomes and quality of life among breast cancer patients highlight the slate of new research presentations Roswell Park
Durable survival effect observed in the largest prospective, non-interventional study completed examining TTFields therapy use in newly diagnosed GBM
Topline data to be presented Saturday, June 1,.
VBI Vaccines Inc. , a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that new interim tumor response data from the.
Chimeric Therapeutics Ltd (ASX:CHM), the only ASX clinical-stage cell therapy company, welcomes the participation of leading US centre Sarah Cannon Research.